Evidence map›Paper›PMID 25473903›Full record

ArticleOncotarget2015

The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer.

Ryunosuke Kogo, Christine How, Naz Chaudary, Jeff Bruce, Wei Shi, Richard P Hill, Payam Zahedi, Kenneth W Yip, Fei-Fei Liu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Low Expression of miR-491-3p Is Correlated with Lymph Node Metastasis in Gastric Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases.International journal of molecular sciences · 2020
    Review
  19. Long noncoding RNACell cycle (Georgetown, Tex.) · 2020
    Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ryunosuke KogoOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Christine HowOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Naz ChaudaryOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Jeff BruceOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Wei ShiOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Richard P HillOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Payam ZahediOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Kenneth W YipOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.
Fei-Fei LiuOntario Cancer Institute, University Health Network (UHN), Toronto, Ontario, Canada.Department of Medical Biophysics, University of Toronto, Toronto, Canada.Department of Radiation Oncology, University of Toronto, Toronto, Canada.Department of Radiation Oncology, Princess Margaret Cancer Centre, UHN, Toronto, Canada.
University Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is the third most common cancer in women worldwide. In the present study, global microRNA profiling for 79 cervical cancer patient samples led to the identification of miR-218 down-regulation in cervical cancer tissues compared to normal cervical tissues. Lower miR-218 expression was associated significantly with worse overall survival (OS), disease-free survival (DFS), and pelvic/aortic lymph node recurrence. In vitro, miR-218 over-expression decreased clonogenicity, migration, and invasion. Survivin (BIRC5) was subsequently identified as an important cervical cancer target of miR-218 using in silico prediction, mRNA profiling, and quantitative real-time PCR (qRT-PCR). Concordant with miR-218 over-expression, survivin knockdown by siRNA decreased clonogenicity, migration, and invasion. YM155, a small molecule survivin inhibitor, significantly suppressed tumor growth and lymph node metastasis in vivo. Our findings demonstrate that the miR-218~survivin axis inhibits cervical cancer progression by regulating clonogenicity, migration, and invasion, and suggest that the inhibition of survivin could be a potential therapeutic strategy to improve outcome in this disease.

Indexed as

3' Untranslated RegionsAnimalsBlotting, WesternCell Line, TumorCell MovementCell SurvivalDose-Response Relationship, DrugFemaleGene Expression Regulation, NeoplasticHEK293 CellsHumansImidazolesInhibitor of Apoptosis ProteinsKaplan-Meier EstimateLymphatic MetastasisMice, SCID3' Untranslated RegionsBIRC5 protein, humanImidazolesInhibitor of Apoptosis ProteinsMicroRNAsMIRN218 microRNA, humanNaphthoquinonessepantroniumSurvivin

Identifiers

PMID25473903
PMCPMC4359219
OpenAlexW1909139530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.